Drawing for MORROWGENIX

USPTO serial 77617054

MORROWGENIX

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
COLEMAN, NICHOLAS A
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MORROWGENIX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Clark D. Gross

Clark D. Gross Law Offices of Clark Gross1800 Century Park EastSuite 600Los Angeles, CA 90067

Goods and services

ClassDescriptionStatusFirst use
001Biological tissue, namely, blood, fat derived stem cells, fat derived collagen, collagen, cells, stem cells, umbilical cords and placentas for scientific and clinical research useACTIVE—
003Cosmetic preparations for skin renewal; non-medicated skin care preparations; skin moisturizer; non-medicated skin care preparation for use in treating sun burn and chapping; sunscreen; skin preparations for UV protection in the nature of sun block; non-medicated skin care preparations for use in cosmetic peels; skin gel; cosmetics; medicated biologic compounds in the form skin soapACTIVE—
005Medicines for the treatment of aging, cosmetic appearance, wrinkles, dermal defects, wound healing, revascularization, skin laxity, skin redundancy, skin deformity, scar tissue, facial aging, facial rejuvenation, facial reconstruction, body rejuvenation, body reconstruction, body contouring, body augmentation, breast augmentation, buttock augmentation, mons augmentation, nasal augmentation, urinary incontinence, and erectile dysfunction; biological tissue, namely, blood, fat derived stem cells, fat derived collagen, collagen, cells, stem cells, umbilical cords and placentas for medical use; pharmaceuticals, namely, pharmaceutical skin lotions, antiinfective preparations, medicated anti-aging skin creams and lotions; medicated biologic compounds in the form of body lotion, skin lotion, skin creams, skin adjuvants, skin astringents, skin stimulants, skin regenerants, skin powder, skin oil, skin gel, skin moisturizer, skin colloid, and skin hydroge; medicated skin serums; biologic product, namely, human allograft, autograft, and xenograft tissue; biologic derivatives, namely, autologous cells, allogeneic cells, and cells for medical or clinical use; medicated serums for treatment of wounds, scars, burns, skin defects, cosmetic appearance, breast augmentation, limb regeneration, limb amputation, aging, wrinkles, dermal defects, wound healing, tissue revascularization, skin laxity, skin redundancy, skin deformity, scar tissue, facial aging, facial rejuvenation, facial reconstruction, body rejuvenation, body reconstruction, body contouring, body augmentation, buttock augmentation, mons augmentation, nasal augmentation, urinary incontinence, and erectile dysfunction; biological derivatives in the nature of cell membranes, cell proteins, extracellular matrix, hormones, neurotransmitters, hormone precursors, neurotransmitter precursors, signal transduction molecules, aromatic hydrocarbons, proteins, amino acids, carbohydrates, nucleic acids, DNA, RNA, phospholipids, lipids, electrolytes, and antibodies for medical use; conditioned media, namely, tissue culture media, tissue culture serums, and tissue culture additives for medical use; lyophilized agents, namely, freeze dried cells, cell extract, cell organelles, protein, lipids, and carbohydrates for medical use; medicated serums for use in tissue culture, scar tissue repair, body augmentation, fat removal, fat augmentation, wound healing, wound repair, tissue regeneration, and anti-aging; dermal filler, injectable dermal fillers, adjuvants for medical purposes; human allograft, autograft, and xenograft tissue; herbals, namely, herbal supplementsACTIVE—
010medical devices, namely, a fat processing device for isolating adipose derived stem cells, precursor/progenitor cells, and/or fibroblasts from fat, and a cell isolation system primarily featuring a cell isolation device to produce fatty tissue enriched with adipose derived stem cells and/or isolate pure populations and subsets of adipose derived stem cells, fibroblasts or dermal, neuron, vascular, cartilage, muscle or bone progenitor/precursor cells; cell isolation devices for treatment of aging, cosmetic appearance, wrinkles, dermal defects, wound healing, revascularization, skin laxity, skin redundancy, scar tissue, facial rejuvenation, facial reconstruction, body rejuvenation, body reconstruction, urinary incontinence, erectile dysfunction, wounds, scars, burns, skin defects, breast augmentation, limb regeneration, limb amputation, tissue revascularization, skin deformity, facial aging, body contouring, body augmentation, buttock augmentation, mons augmentation, and nasal augmentationACTIVE—
044Cosmetic and plastic surgeryACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 17, 2012MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 17, 2012ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 17, 2012EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Feb 16, 2012EX4GSOU EXTENSION 4 GRANTED—
Feb 9, 2012EXT4SOU EXTENSION 4 FILED—
Feb 9, 2012EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 2, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Aug 1, 2011EX3GSOU EXTENSION 3 GRANTED—
Jul 26, 2011EXT3SOU EXTENSION 3 FILED—
Jul 26, 2011EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 5, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Jan 4, 2011EX2GSOU EXTENSION 2 GRANTED—
Jan 4, 2011AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 7, 2010EXT2SOU EXTENSION 2 FILED—
Dec 7, 2010EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 28, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Jul 26, 2010EX1GSOU EXTENSION 1 GRANTED—
Jul 26, 2010EXT1SOU EXTENSION 1 FILED—
Jul 26, 2010EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 16, 2010NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 24, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 4, 2009NPUBNOTICE OF PUBLICATION—
Oct 20, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Oct 19, 2009CNEAEXAMINERS AMENDMENT MAILED—
Oct 19, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 19, 2009XAECEXAMINER'S AMENDMENT ENTERED—
Oct 19, 2009CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 19, 2009ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Oct 2, 2009PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Sep 24, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Sep 24, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 23, 2009CNEAEXAMINERS AMENDMENT MAILED—
Sep 22, 2009XAECEXAMINER'S AMENDMENT ENTERED—
Sep 22, 2009CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 22, 2009CNEAEXAMINERS AMENDMENT MAILED—
Sep 22, 2009XAECEXAMINER'S AMENDMENT ENTERED—
Sep 22, 2009CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 21, 2009CNEAEXAMINERS AMENDMENT MAILED—
Sep 18, 2009XAECEXAMINER'S AMENDMENT ENTERED—
Sep 18, 2009CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 9, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 9, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 8, 2009ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jul 27, 2009CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 27, 2009CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 6, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 6, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 2, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 1, 2009TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 20, 2009CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 19, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 17, 2009DOCKASSIGNED TO EXAMINER—
Jan 2, 2009AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Jan 2, 2009ALIEASSIGNED TO LIE—
Dec 15, 2008PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Nov 22, 2008MPMKNOTICE OF PSEUDO MARK MAILED—
Nov 21, 2008NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance